Fund raising likely to be completed by Feb-March 2018: Panacea Biotec

In an interview with CNBC-TV18, Rajesh Jain, Joint MD at Panacea Biotec spoke about the results, his outlook for the company as well as the business developments.

The company has focused more on the branded pharmaceutical and vaccine business in the private market and also on growing the differentiated products in the portfolio, where competition is limited and complexity is high, he said.

Speaking about fund raising, he said, “The fund raising plan is going pretty well and we have had the board, as well the shareholders' approval in place. We are doing the roadshows and there is a big interest of investment in Panacea Biotec from several investors.” the process is expected to get completed by February-March of FY18, he added.

For full interview, watch accompanying video...